We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) just came out with quarterly earnings of $1.91 per share, beating the Zacks Consensus Estimate of $1.55 per share. This compares to earnings of $2.56 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 23.23%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.66 per share when it actually produced earnings of $1.48, delivering a surprise of -10.84%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.65 billion for the quarter ended June 2018, surpassing the Zacks Consensus Estimate by 9.08%. This compares to year-ago revenues of $7.14 billion. The company has topped consensus revenue estimates three times over the last four quarters.
Total product sales for the quarter were $5.5 billion. HIV product sales were $3.7 billion, while HCV product sales totaled $1.0 billion. HCV sales declined, primarily due to increased competition.
Gilead’s effective tax rate and non-GAAP effective tax rate in the second quarter of 2018 were 12.8% and 13.4% compared to 24.3% and 22.8% in the first quarter of 2018.
Management reiterated its full-year net product sales guidance. The company raised its diluted, adjusted EPS guidance range to $1.50 - $1.60 per share from the previously-announced $1.41 - $1.51 per share.
Through 4:11 pm EST, shares of Gilead were down 1.4% to $77.80 in after-hours trading.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Gilead shares have added about 8.4% since the beginning of the year versus the S&P 500's gain of 5.5%.
What's Next for Gilead?
While Gilead has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Gilead was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.56 on $5.19 billion in revenues for the coming quarter and $6.15 on $20.78 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates
Gilead Sciences (GILD - Free Report) just came out with quarterly earnings of $1.91 per share, beating the Zacks Consensus Estimate of $1.55 per share. This compares to earnings of $2.56 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 23.23%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.66 per share when it actually produced earnings of $1.48, delivering a surprise of -10.84%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.65 billion for the quarter ended June 2018, surpassing the Zacks Consensus Estimate by 9.08%. This compares to year-ago revenues of $7.14 billion. The company has topped consensus revenue estimates three times over the last four quarters.
Total product sales for the quarter were $5.5 billion. HIV product sales were $3.7 billion, while HCV product sales totaled $1.0 billion. HCV sales declined, primarily due to increased competition.
Gilead’s effective tax rate and non-GAAP effective tax rate in the second quarter of 2018 were 12.8% and 13.4% compared to 24.3% and 22.8% in the first quarter of 2018.
Management reiterated its full-year net product sales guidance. The company raised its diluted, adjusted EPS guidance range to $1.50 - $1.60 per share from the previously-announced $1.41 - $1.51 per share.
Through 4:11 pm EST, shares of Gilead were down 1.4% to $77.80 in after-hours trading.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Gilead shares have added about 8.4% since the beginning of the year versus the S&P 500's gain of 5.5%.
What's Next for Gilead?
While Gilead has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Gilead was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.56 on $5.19 billion in revenues for the coming quarter and $6.15 on $20.78 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.